Drug Index

Mechanism :

Pegaspargase is a modified version of L-asparaginase, conjugated with polyethylene glycol. Asparagine depletion in leukemic cells leads to inhibition of protein synthesis and apoptosis. Asparaginase is cycle-specific for the G1 phase of the cell cycle.


Indication :

  • Acute lymphoblastic leukemia as a first-line agent
  • Treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to native forms of L-asparaginase.

Contraindications :

History of serious allergic reactions to pegaspargase or any component of the formulation; Severe hepatic impairment


Dosing :

IM, IV:
2500 units/sqm. Administer every 14 days.

Adverse Effect :

Increased serum transaminases, Hypersensitivity reaction, thrombosis, hyperglycemia, pancreatitis, blood coagulation disorder.


Interaction :

Baricitinib: Immunosuppressants may enhance the immunosuppressive effect of Baricitinib.
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants.
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity.
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of live vaccines.



Hepatic Dose :

Mild to moderate hepatic impairment: Dose adjustment may not be required.
Severe hepatic impairment: Use is contraindicated.

If hepatotoxicity develops during therapy:
If the ALT or AST level is greater than 3 but less than 5 times the upper limit of normal (ULN): therapy can be continued.
If the ALT or AST level is greater than 5 but less than 20 times ULN: Stop therapy till the ratio is less than 3 times the upper limit of normal, then continue.
If the ALT or AST is greater than 20 ULN: If the levels take longer than 1 week to return to less than 3 times upper limit of normal, stop therapy completely.
If direct bilirubin levels are less than 3 mg/dl: therapy can be continued.
If direct bilirubin levels are between 3.1mg/dl and 5 mg/dl: Stop therapy till bilirubin reaches less than 2 mg/dl and switching to another asparaginase product may need to be considered.
If direct bilirubin levels are greater than 5 mg/dl: Stop pegaspargase therapy, and do not switch to or administer any another asparaginase product.
09/28/2020 08:15:44 Pegaspargase
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0